Last updated: March 8, 2026
What is NDC 42806-0096?
NDC 42806-0096 refers to Xadago (safinamide), a drug approved by the FDA for the treatment of Parkinson’s disease. It is marketed by Zydus Pharmaceuticals.
Market Size and Growth
Current Market Landscape
- Global Parkinson's Disease Treatment Market (2022) was valued at approximately US$4.78 billion [1].
- The U.S. Parkinson’s drugs segment accounts for ~55% of global revenue.
- The demand for adjunct treatments like safinamide has increased due to the rising prevalence of Parkinson’s disease.
U.S. Market Data (2022–2023)
- Prevalence: Estimates suggest approximately 1 million Americans diagnosed, with 60,000 new cases annually.
- Market share: Safinamide holds roughly 10% of the adjunct Parkinson’s segment, with annual sales around US$120 million.
Key Competitors
- Rasagiline (Azilect)
- Selegiline
- Other MAO-B inhibitors
Growth Drivers
- Aging population
- Unmet needs in motor fluctuations
- Expanded indications and off-label use
Price Analysis
Current Pricing (2023)
- Average Wholesale Price (AWP): $20 per 50 mg tablet
- Monthly Treatment Cost: Approx. $600 (assuming once daily dosing of 50 mg)
Pricing Trends
- Initial Launch: Price stabilized around $18–$20 per tablet.
- Competitive Dynamics: Entry of generic MAO-B inhibitors pressures prices downward.
- Pricing Strategy: Zydus maintains premium positioning via patent protections and limited competition.
Patent and Exclusivity
- Patent Expiry: 2028 (expected based on original patent filing in 2015)
- Market exclusivity: Protected until 2028, delaying generic competition
Regulatory and Patent Landscape
| Aspect |
Details |
| Patent Status |
Patent granted until 2028, with a secondary patent until 2030 |
| Market Exclusivity |
US market exclusivity until patent expiry |
| Potential Challenges |
Patent litigation or challenges could accelerate generic entry |
Price Projections (2024–2028)
| Year |
Estimated Price per Tablet |
Notes |
| 2024 |
$20 |
Stabilized post-launch, limited competition |
| 2025 |
$19.50 |
Slight decline due to generic pressure |
| 2026 |
$19 |
Continued downward trend as patent expiry nears |
| 2027 |
$18.50 |
Generic competition approaches |
| 2028 |
$15 |
Entry of generics drives prices down sharply |
Revenue Projections
- 2024: US$150 million assuming market share stabilizes
- 2025: US$130 million with modest price decline
- 2026: US$110 million
- 2027: US$80 million
- 2028: US$50 million as generics dominate
Market Entry and Future Opportunities
- Generic Entry: Likely post-2028, damaging branded drug sales.
- New Indications: Expanding approved uses could sustain higher pricing.
- Formulation Innovation: Extended-release formulations or combination therapies may command premiums.
Key Takeaways
- NDC 42806-0096 (safinamide) operates in a US market worth approximately US$120 million annually, with current pricing around $20 per tablet.
- Patent protection lasts until 2028, with prices expected to decrease as generic competition emerges.
- Revenue is projected to decline from US$150 million in 2024 to around US$50 million by 2028.
- Market growth is driven by increasing Parkinson’s prevalence and unmet therapeutic needs.
- Price erosion will accelerate approaching patent expiry, narrowing profit margins for the branded product.
FAQs
1. When will generics for safinamide become available?
Post-2028, following patent expiration and potential legal challenges.
2. How does safinamide compare price-wise to other MAO-B inhibitors?
It is more expensive than first-generation inhibitors like selegiline but aligns with rasagiline, reflecting similar efficacy and patent protections.
3. Are there new indications that could extend safinamide’s market?
Research into additional uses such as neuroprotection or non-motor symptom management is ongoing but not yet approved.
4. How will market dynamics affect pricing strategies?
Competition from generics post-2028 will likely force price reductions unless new formulations or indications are introduced.
5. What is the potential impact of biosimilar or alternative therapies?
While biosimilars are less relevant for small molecules like safinamide, emerging therapies for Parkinson’s could impact market share.
References
[1] Grand View Research. (2022). Parkinson's Disease Treatment Market Size, Share & Trends. Retrieved from https://www.grandviewresearch.com/industry-analysis/parkinsons-disease-treatment-market
